<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:51:25Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27997" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27997</identifier><datestamp>2026-09-24T06:33:23Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Tsakiridis, Theos</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Ahmadi, Elham</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-10-13T18:12:37Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-10-13T18:12:37Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27997</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/14668</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Currently, many patients with early-stage localized prostate cancer (PrCa) (D’Amico: low &#xd;
risk or low-intermediate risk) do not receive immediate therapy but are monitored within &#xd;
systematic AS programs. Prospective trials showed rates of stage reclassification and &#xd;
progression to the treatment of 20–40% over 2–5 years. However, in certain patients, PrCa&#xd;
progresses rapidly to an advanced stage that requires combined modality therapies, which &#xd;
carry increased risk for toxicity and poor outcomes. There is a need to identify biomarkers &#xd;
that can predict the risk for disease progression in this population. Research showed that &#xd;
dysregulation of metabolism is an important hallmark of cancer progression. Here, we &#xd;
pursued a pilot investigation of enzymes of de novo lipogenesis [ATP-citrate lyase &#xd;
(ACLY), Acetyl-CoA Carboxylase (ACC)], lipid oxidation [a-Methylacyl-CoA Racemase &#xd;
(AMACR)], glucose uptake [facilitative glucose transporter 1 (GLUT1)], and folate –&#xd;
glutamate metabolism (PSMA: prostate-specific membrane antigen) as potential &#xd;
biomarkers of PrCa progression in AS patients. With ethics approval from the Hamilton &#xd;
Integrated Research Ethics Board (HiREB), 40 AS patients were accrued prospectively &#xd;
from the Niagara Health System PrCa diagnostic program clinics and were asked to donate &#xd;
their biopsy tissue. 28 patients progressed on repeat biopsies at 12 or 24 months after initial &#xd;
diagnosis and were included in the “Progressed” group, and 12 did not who were included &#xd;
in the “Non-Progressed” group. Baseline diagnostic prostate core biopsy tissues of both &#xd;
groups were evaluated with H&amp;E and immunohistochemistry (IHC) staining for ACLY, &#xd;
ACC, GLUT1, AMACR and PSMA expression (quantified by H-score). H-scores were &#xd;
evaluated in benign and malignant components (epithelial cells) and were compared &#xd;
between the two groups of patients. We observed statistically significant increased GLUT1 &#xd;
expression in malignant epithelial cells of the progressed group compared to the non-progressed group. Also, we found statistically significant increased PSMA expression in &#xd;
the benign epithelial cells of the progressed group compared to the non-progressed group. &#xd;
Further, our results demonstrated a statistically significant increase in ACLY and ACC &#xd;
expression in malignant epithelial cells compared to benign epithelial cells in the &#xd;
progressed group, while AMACR was detected solely in the malignant component. &#xd;
Overall, the results of this pilot study are consistent with the notion of induction of &#xd;
glycolytic metabolism, de novo lipogenesis and increased PSMA expression associated &#xd;
with the risk for PrCa progression. The levels of expression of PSMA within benign &#xd;
epithelial cells and GLUT1 within malignant epithelial cells may have value as predictive &#xd;
markers of risk for PrCa progression in AS patients. Future studies should investigate this &#xd;
concept systematically in larger AS cohorts.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Currently, many patients with localized prostate cancer do not receive immediate therapy &#xd;
and are monitored within systematic active surveillance (AS) programs. The main aim of &#xd;
AS management is to prevent overtreatment and treatment-related complications in &#xd;
patients who would otherwise have a good quality of life despite dealing with prostate &#xd;
cancer. However, many of these patients, especially those with low intermediate-risk &#xd;
prostate cancer have a significant risk for disease progression and metastasis. &#xd;
Additionally, there is a lack of promising tissue biomarkers to predict the risk for &#xd;
progression in AS patients at the time of initial diagnosis. Research showed that &#xd;
metabolism dysregulation is an essential hallmark of cancer progression, including &#xd;
prostate cancer. In this pilot study, we examined whether the expression of enzymes &#xd;
involved in lipid, glucose and protein metabolism could have value as biomarkers of risk &#xd;
for prostate cancer progression in patients managed with AS. The expression of five &#xd;
metabolic enzymes (ACLY, ACC, GLUT1, AMACR and PSMA) was examined in tumor &#xd;
and benign regions of diagnostic biopsies of the prostate obtained from men managed &#xd;
with AS. Our early results suggest that the expression of enzymes of protein (PSMA) and &#xd;
glucose (GLUT1) metabolism may have value as biomarkers of risk for prostate cancer &#xd;
progression and should be investigated further in systematic studies.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Prostate Cancer, Metabolic Enzymes, ACLY, ACC, GLUT1, PSMA, AMACR, Active Surveillance</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Evaluation of metabolic enzymes as predictive biomarkers of risk for prostate cancer progression</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>